BioMarin Pharma (BMRN) Tops Q4 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.94 -1.75%
Revenue Growth %: +31.4%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +31.4%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.00, which may not compare to the analyst estimate of ($0.06). Revenue for the quarter came in at $537.5 million versus the consensus estimate of $537.62 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.61. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 billion, versus the consensus of $2.58 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital
- Barclays says AI trade is maturing, favors greater diversification
- Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
